Company intelligence / Profile preview
Daiichi Sankyo Co., Ltd.
Tokyo, Tokyo-to, Japandaiichisankyo.com ↗
- Ownership
- Public · 4568
- Development stage
- Other
01
Overview
Daiichi Sankyo has multiple approved drugs including Enhertu (fam-trastuzumab deruxtecan) for breast cancer and recently approved Datroway (datopotamab deruxtecan) for HR-positive, HER2-negative breast cancer. The company has a robust pipeline with 8 registration trial readouts expected in 2025[10].
- Therapeutic areas
- CardiovascularMetabolic DisordersImmunologyDermatologyOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Antibody-drug conjugates (ADCs)small molecules
- Industry
- Pharma
02
Drug pipeline
157 assets156 more assets in the full pipeline.
03
Partnerships
AstraZeneca (for Enhertu and Datroway)Eli Lilly & Company (for Effient)Wayfinder Biosciences (2025)Nosis Biosciences (2025)Terumo Vietnam (2025)
04
Financials
- Market cap
- $31.9B
- Total revenue
- $13.4B
- Enterprise value
- $30.7B
Beyond the preview
Go deeper on Daiichi Sankyo Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Daiichi Sankyo Co., Ltd..